Delving into the Latest Updates on Vandetanib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib (JAN/USAN/INN)

+ [18]

Target

BRK x EGFR x Eph x RET x SRC family x Tie-2 x VEGFR

Action

inhibitors, antagonists

Mechanism

BRK inhibitors(Tyrosine-protein kinase BRK inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Eph inhibitors(Ephrin receptor inhibitors)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

RET Mutation-Positive Medullary Thyroid CancerAdvanced Thyroid Gland Medullary CarcinomaMetastatic Thyroid Gland Medullary Carcinoma+ [2]

Inactive Indication

Advanced biliary tract cancerAdvanced breast cancerAdvanced Colorectal Adenocarcinoma+ [60]

Originator Organization

AstraZeneca Pharmaceuticals Co. Ltd.

Active Organization

IPR Pharmaceuticals, Inc.

Genzyme Corp.Sanofi-Aventis Korea Co., Ltd.

+ [5]

Inactive Organization

AstraZeneca PLC

Celgene Corp.

Dana-Farber Cancer Institute, Inc.

License Organization

AstraZeneca PLC

Genzyme Corp.

Drug Highest PhaseApproved

First Approval Date

United States (06 Apr 2011),

Thyroid Cancer, Medullary

RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H24BrFN4O2

InChIKeyUHTHHESEBZOYNR-UHFFFAOYSA-N

CAS Registry443913-73-3

Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI).
The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase inhibitor therapy (Lenvatinib or Sorafenib for differentiated thyroid cancer [which includes papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid cancer]; and Cabozantinib or Vandetanib for medullary thyroid cancer) through adaptive (intermittent) versus conventional (continuous) regimen.

Start Date06 Aug 2018

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

EUCTR2017-002517-64-GB

/ Not yet recruitingPhase 1/2

An open label, single-arm, Phase I/II study of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with hepatocellular carcinoma (HCC) without curative options - VALENCIA

Start Date15 Dec 2017

Sponsor / Collaborator

Biocompatibles UK Ltd.

100 Clinical Results associated with Vandetanib

Login to view more data

100 Translational Medicine associated with Vandetanib

Login to view more data

100 Patents (Medical) associated with Vandetanib

Login to view more data

1,785

Literatures (Medical) associated with Vandetanib

31 Dec 2025·Virulence

Ponatinib and other clinically approved inhibitors of Src and Rho-A kinases abrogate dengue virus serotype 2- induced endothelial permeability

Article

Author: Awasthi, Mansi ; Modak, Ayan ; Sobha, Archana ; Sreekumar, Easwaran ; Mishra, Srishti Rajkumar

Severe dengue often presents as shock syndrome with enhanced vascular permeability and plasma leakage into tissue spaces. In vitro studies have documented the role of Src family kinases (SFKs) and RhoA-kinases (ROCK) in dengue virus serotype 2 (DENV2)-induced endothelial permeability. Here, we show that the FDA-approved SFK inhibitors Bosutinib, Vandetanib and Ponatinib, as well as the ROCK inhibitors, Netarsudil and Ripasudil significantly inhibit DENV2-induced endothelial permeability. In cultured telomerase immortalized human microvascular endothelial cells (HMEC-1), treatment with these inhibitors reduced the phosphorylation of VE-Cadherin, Src and myosin light chain 2 (MLC2) proteins that were upregulated during DENV2 infection. It also prevented the loss of VE-Cadherin from the inter-endothelial cell junctions induced by viral infection. In in-vivo studies using DENV2-infected AG129 IFN receptor-α/β/γ deficient mice, ponatinib, when administered 24 h post-infection onwards, demonstrated significant benefits in improving body weight, clinical outcomes, and survival rates. While all virus-infected, untreated mice died by day-10 post-infection, 80% of the ponatinib-treated mice survived, and approximately 60% were still alive at the end of the 15-day observation period. The treatment also significantly reduced disease severity factors such as vascular leakage, thrombocytopenia; mRNA transcript levels of proinflammatory cytokines such as IL-1β and TNF-α; and restored liver function. Comparable effects were observed even when ponatinib treatment was initiated after symptom onset. The results highlight ponatinib as an effective therapeutic option in severe dengue; and also a similar potential for other FDA- approved SFK and ROCK inhibitors.

01 Jun 2025·TISSUE & CELL

Baicalin reduced vandetanib induced myocardial injury by regulating redox balance and NLRP3 inflammasome pathway

Article

Author: Zhang, Xiaodong ; Huang, Guangyi ; Zhuang, Ruijuan ; Liu, Fengqi ; Liu, Yankui ; Du, Yingqiang ; Wang, Xiaoyan ; Xiao, Wang ; Sun, Jialong ; Zhang, Zhixuan ; Ma, Yiyi ; Liu, Qian ; Wang, Fen ; Gao, Changzheng ; Gu, Xin ; Li, Jianwei

Baicalin has garnered attention for its potential therapeutic effects on various cardiovascular conditions, including drug-induced cardiac injury. In this study, we utilized a murine model to explore the protective role of baicalin against cardiac dysfunction induced by vandetanib. Our findings indicate that baicalin administration effectively ameliorated vandetanib-induced cardiac injury. Echocardiographic assessments revealed significant improvements in the myocardial contraction in mice treated with baicalin compared with those receiving vandetanib alone. Histological analysis revealed reduced myocardial inflammation and fibrosis in baicalin-treated mice. Specifically, baicalin suppressed proinflammatory factors such as IL-6, IL-1β, and TNF-α, thereby attenuating the inflammatory response triggered by vandetanib. Moreover, baicalin inhibited myocardial apoptosis, as evidenced by decreased levels of Caspase-3, Bax, and p53, while concurrently elevated expression of the antiapoptotic protein Bcl-2. Mechanistically, baicalin-mediated inhibition of the NLRP3 inflammasome pathway has emerged as a crucial aspect of its cardioprotective action and promotes redox balance in myocardial cells under vandetanib-induced oxidative stress. It upregulated the expression of the antioxidant enzymes SOD1 and SOD2, thereby mitigating intracellular ROS accumulation and preserving cardiomyocyte viability. In conclusion, our study highlights baicalin as a promising therapeutic agent for mitigating vandetanib-induced cardiac injury through multiple mechanisms, including anti-inflammatory, antiapoptotic, antioxidant, and NLRP3 inflammasome inhibitory actions. Our findings will be further validated in clinical trials and explore the translational potential of baicalin in treating drug-induced cardiotoxicity in humans.

01 May 2025·PHARMACOLOGICAL RESEARCH

DIORS: Enhancing drug-target interaction prediction via structure and signature integrated-driven approach and discovering potential targeted molecules

Article

Author: Hu, Wanting ; Jiang, Xuyong ; Han, Lu ; Zhao, Xueru ; Luo, Dan ; Tang, Yiran ; Xiao, Zhiyong ; Gao, Shengqiao ; Zhou, Wenxia ; Zhang, Yongxiang

Drug-target interaction prediction is critical for drug development. Through the integration of structural and transcriptional signature information, molecules both binding to the target and producing therapeutic activities could be found out to improve targeted drug prediction. Therefore, the approaches that integrate the two types of data are worth exploring. Here, we present an integrated method named Data Integration Oriented Repurposing Strategy (DIORS) combining molecular docking and gene-signature matching to enhance the prediction of protein-targeted drugs. The StandardScaler algorithm was selected after evaluation of five algorithms and was used in DIORS. Surface Plasmon Resonance (SPR) was used to verify the molecular affinities and cell-based assays were used to verify the activities of DIORS predicted molecules. In Piezo1-targeted molecule prediction, among the top ten predicted molecules by DIORS, four of them, namely gefitinib, rifaximin, bosutinib and vandetanib, exhibited binding affinities. In the prediction of TLR4/MD2-targeted anti-inflammatory molecules, among the top ten predicted molecules, three of them, namely enoxolone, dabrafenib and ponatinib, exhibit both high binding affinities and anti-inflammatory activities. The results demonstrated that DIORS can serve as a better approach with high performance to predict and find new targeted drugs by combining structural and signature information.

21

News (Medical) associated with Vandetanib

30 Sep 2024

·www.fda.gov

FDA approves selpercatinib for medullary thyroid cancer with a RET mutation

On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. Selpercatinib received accelerated approval for this indication for patients 12 years of age and older in 2020. On May 29, 2024, the FDA granted accelerated approval for this indication to pediatric patients 2 years of age and older. Efficacy was evaluated in LIBRETTO-531 (NCT04211337), a randomized, multicenter, open-label study in adults and adolescents with advanced or metastatic RET-mutant MTC. Patients were randomized (2:1) to receive either selpercatinib (160 mg twice daily) or physicians’ choice of cabozantinib (140 mg once daily) or vandetanib (300 mg once daily). Patients were stratified based on RET mutation (M918T vs. other) and intended treatment if randomized to the control arm (cabozantinib vs. vandetanib). The main efficacy outcome measure was progression-free survival (PFS), as determined by a blinded independent review committee according to RECIST v1.1. Median PFS was not reached (NR) (95% CI: not evaluable [NE], NE) in the selpercatinib arm and 16.8 months (95% CI: 12.2, 25.1) in the cabozantinib/vandetanib arm (Hazard Ratio 0.280 [95% CI: 0.165, 0.475] p-value <0.0001). The clinical benefit of selpercatinib was supported by a pre-specified analysis of patient-reported comparative side effect impact; patients in the selpercatinib arm reported less time with severe side effect bother than those receiving cabozantinib or vandetanib. The most common adverse reactions (≥25%) were hypertension, edema, dry mouth, fatigue, and diarrhea. The most common Grade 3 or 4 laboratory abnormalities (≥5%) were decreased lymphocytes, increased alanine aminotransferase (ALT), decreased neutrophils, increased alkaline phosphatase (ALP), increased blood creatinine, decreased calcium, and increased aspartate aminotransferase (AST). The recommended selpercatinib dose for pediatric patients 2 to less than 12 years of age is based on body surface area and is based on weight for patients 12 years of age and older. See the prescribing information for specific dosing information. Expedited Programs This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted priority review, breakthrough designation, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X: @FDAOncologyExternal Link Disclaimer. Content current as of: 09/30/2024 Regulated Product(s) Drugs Content current as of: 09/30/2024 Regulated Product(s) Drugs Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

Drug ApprovalPriority ReviewAccelerated ApprovalOrphan DrugClinical Result

09 Aug 2024

·www.fda.gov

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

On May 8, 2020, the Food and Drug Administration granted accelerated approval to selpercatinib (RETEVMO, Eli Lilly and Company) for the following indications: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Efficacy was investigated in a multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001) in patients whose tumors had RET alterations. Identification of RET gene alterations was prospectively determined in local laboratories using either next generation sequencing, polymerase chain reaction, or fluorescence in situ hybridization. The main efficacy outcome measures were overall response rate (ORR) and response duration determined by a blinded independent review committee using RECIST 1.1. Efficacy for RET-fusion-positive NSCLC was evaluated in 105 adult patients, previously treated with platinum chemotherapy. The ORR was 64% (95% CI: 54%, 73%); 81% of responding patients had responses lasting 6 months or longer. Efficacy was also evaluated in 39 patients who never received systemic treatment. The ORR for these patients was 85% (95% CI: 70%, 94%); 58% of responding patients had responses lasting 6 months or longer. Efficacy for advanced or metastatic RET-mutant MTC was investigated in adults and pediatric patients (≥12 years of age). The trial enrolled patients previously treated with cabozantinib, vandetanib, or both, and patients who had not received these drugs. The ORR for the 55 previously treated patients was 69% (95% CI: 55%, 81%); 76% of responding patients had responses lasting 6 months or longer. Efficacy was also evaluated in 88 patients not previously treated with an approved therapy for MTC. The ORR for these patients was 73% (95% CI: 62%, 82%); 61% of responding patients had responses lasting 6 months or longer. Efficacy for RET fusion-positive thyroid cancer was evaluated in adults and pediatric patients (≥12 years of age). The trial enrolled 19 patients who were radioactive iodine-refractory (if appropriate) and had received another prior systemic treatment, and 8 patients who were RAI-refractory and had not received any additional therapy. The ORR for the 19 previously treated patients was 79% (95% CI: 54%, 94%); 87% of responding patients had responses lasting 6 months or longer. Efficacy was also evaluated in 8 patients who received RAI and no other subsequent therapy. All 8 patients responded (95% CI: 63%, 100%) and 75% had responses lasting 6 months or longer. The most common adverse reactions, including laboratory abnormalities, (≥ 25%) were increased aspartate aminotransferase, increased alanine aminotransferase, increased glucose, decreased leukocytes, decreased albumin, decreased calcium, dry mouth, diarrhea, increased creatinine, increased alkaline phosphatase, hypertension, fatigue, edema, decreased platelets, increased total cholesterol, rash, decreased sodium, and constipation. The recommended selpercatinib dose is weight based—120 mg for patients less than 50 kg, and 160 mg for those 50 kg or greater. Selpercatinib is taken orally twice daily with or without food; or with food when co-administered with a proton pump inhibitor. View full prescribing information for RETEVMO. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was approved 3 months prior to the FDA goal date. This application was granted accelerated approval based on overall response rate and response duration. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials. This application was granted priority review, breakthrough therapy, and orphan drug designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncologyExternal Link Disclaimer.

Clinical ResultDrug ApprovalPriority ReviewBreakthrough TherapyAccelerated Approval

09 Aug 2024

·www.fda.gov

FDA approves pralsetinib for RET-altered thyroid cancers

On December 1, 2020, the Food and Drug Administration approved pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Efficacy was investigated in a multicenter, open label, multi-cohort clinical trial (ARROW, NCT03037385) in patients whose tumors had RET gene alterations. Identification of RET gene alterations was prospectively determined in local laboratories using either next generation sequencing, fluorescence in situ hybridization, or other tests. The main efficacy outcome measures were overall response rate (ORR) and response duration determined by a blinded independent review committee using RECIST 1.1. Efficacy for advanced or metastatic RET-mutant MTC was evaluated in 55 patients who received prior cabozantinib or vandetanib. The ORR for these patients was 60% (95% CI: 46%, 73%); 79% of responding patients had responses lasting 6 months or longer. Efficacy was also evaluated in 29 patients with RET-mutant MTC who did not receive prior cabozantinib or vandetanib. The ORR was 66% (95% CI: 46%, 82%); 84% of patients had responses lasting 6 months or longer. Efficacy for patients with RET fusion-positive thyroid cancer was evaluated in 9 patients who were radioactive iodine-refractory. The ORR was 89% (95% CI: 52%, 100%); all responding patients had responses lasting 6 months or longer. The most common adverse reactions (≥25%) were constipation, hypertension, fatigue, musculoskeletal pain, and diarrhea. The most common Grade 3-4 laboratory abnormalities (≥2%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased phosphate, decreased calcium (corrected), decreased sodium, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), decreased platelets, and increased alkaline phosphatase. The recommended pralsetinib dose in adults and pediatric patients 12 years and older is 400 mg orally once daily on an empty stomach with no food intake for at least 2 hours before and at least 1 hour after taking pralsetinib. View full prescribing information for GAVRETO. This review used the Real-Time Oncology Review (RTOR) pilot program and Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application 3 months ahead of the FDA goal date. This application was granted accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This application was granted priority review, breakthrough therapy, and orphan drug designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncologyExternal Link Disclaimer. Content current as of: 12/01/2020 Regulated Product(s) Drugs Prescription Drugs 12/01/2020 Drugs Prescription Drugs Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

Drug ApprovalPriority ReviewClinical ResultAccelerated ApprovalOrphan Drug

100 Deals associated with Vandetanib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06407	Vandetanib	L01XE12	DB05294

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
RET Mutation-Positive Medullary Thyroid Cancer	European Union	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Iceland	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Liechtenstein	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Norway	Sanofi	01 Feb 2023
Advanced Thyroid Gland Medullary Carcinoma	South Korea	Sanofi-Aventis Korea Co., Ltd.	24 May 2013
Metastatic Thyroid Gland Medullary Carcinoma	South Korea	Sanofi-Aventis Korea Co., Ltd.	24 May 2013
Thyroid Cancer, Medullary	United States	Genzyme Corp.	06 Apr 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	IPR Pharmaceuticals, Inc.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	AstraZeneca AB	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	AstraZeneca Pharmaceuticals Co. Ltd.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	China	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	AstraZeneca Pharmaceuticals Co. Ltd.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	AstraZeneca AB	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	IPR Pharmaceuticals, Inc.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Brazil	Genzyme Corp.	17 Sep 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03291379 (VEROnA, Pubmed) Manual	Phase 1	Neoplasms	8	Vandetanib-Eluting Radiopaque Embolics	lbwflbdykx(qgafkuxqcr) = There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. ggvldnmpet (zrltyigsdy )	Positive	05 May 2022
NCT01934335 (CTgov)	Phase 2	Invasive Mammary Carcinoma	12	Vandetanib (Vandetanib)	fzdganmcok(ahriyeukht) = rqmjkhxbws udtfankepx (puygldwnaq, 0.08) View more	-	01 Nov 2021
				Placebo (Placebo)	fzdganmcok(ahriyeukht) = nkrbgtplor udtfankepx (puygldwnaq, 0.05) View more
NCT01586624 (CTgov)	Phase 1	Non-Small Cell Lung Cancer	61	Selumetinib+Vandetanib (Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib))	lvwdlaygpy = yopduunsos jbjqifkjgx (zsdocbxqwz, ijfqryrozi - eyjsgbvige) View more	-	07 Oct 2021
				Selumetinib+Vandetanib (Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib))	lvwdlaygpy = bwwiedxekm jbjqifkjgx (zsdocbxqwz, vgtcxpbhpb - mccvhmoxmn) View more
NCT01582191 (Pubmed \| ESMO Open) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	80	vandetanib+everolimus	drbzntjodn(iezfmtsayj) = lrgnbxeldw bbjgtcllzr (ohvenovccd, 3.4 - 7.3) View more	Positive	01 Apr 2021
NCT03291379 (VEROnA, CTgov)	Early Phase 1	Hepatocellular Carcinoma \| Metastatic Colorectal Carcinoma	8	BTG-002814	eylktiydtb = dgyxhzande hmyvmtrqot (rlfvmrjpdn, ejybxocvfb - ssbtjglccr) View more	-	03 Feb 2021
NCT03630120 (CTgov)	Phase 2	Thyroid Cancer, Follicular \| Differentiated Thyroid Gland Carcinoma \| Papillary thyroid cancer ... View more	6	Sorafenib+Lenvatinib (Standard of Care: DTC)	jcrpopsrys(frcrpgfsgr) = sqyzupeunm fpkrnohaeb (uwyqzsvzjf, wqmlttnrlb - uuxnbxsdug) View more	-	22 Jan 2021
				Sorafenib+Lenvatinib (Adaptive Care: DTC)	jcrpopsrys(frcrpgfsgr) = mcxagjzixx fpkrnohaeb (uwyqzsvzjf, jchxrgcdvi - hjgiilskuw) View more
NCT01183559 (CTgov)	Phase 1	Esophageal Carcinoma \| Locally Advanced Gastroesophageal Junction Adenocarcinoma	9	External Beam Radiation Therapy (RT)+Carboplatin+Vandetanib+Paclitaxel+FU	mglaciwsid = fynptnkrnv tdumbzpafu (mutmbtpnup, xbjywvamya - gnlexiwlfp) View more	-	22 Jan 2021
NCT01414426 (CTgov)	Phase 2	Squamous cell carcinoma of the oral cavity \| Verrucous Carcinoma \| Precancerous Conditions	20	biopsy+vandetanib (Arm I (Chemoprevention))	strusqdqsu = ooqntmpock jjsfblbesq (wecnidsnls, noxpfekuvm - ywffkrddej) View more	-	14 Jan 2021
				placebo (Arm II (Placebo))	strusqdqsu = dwpeitfcpq jjsfblbesq (wecnidsnls, iieslwvmee - tepsdqvdsv) View more
NCT00514046 (CTgov)	Phase 1/2	Familial Medullary Thyroid Carcinoma \| Multiple Endocrine Neoplasia Type 2b \| Thyroid Cancer, Medullary	17	Vandetanib (All Participants)	povsyahxkt = wvlptkuaqi dhvtsggkpq (wljjcjcqmv, qronuybanz - ecsqklwegv) View more	-	22 Dec 2020
				Vandetanib (Vandetanib: First 100 mg/m^2, Then 150 mg/m^2)	tmufghwafe = wuvbqlyjnj ecvqwuhmmk (pfpimfmfol, pfeordaxym - danchyocmd) View more
NCT02530411 (FURVA, ESMO2020)	Phase 2	Estrogen receptor positive breast cancer	165	Vandetanib 300mg + Fulvestrant 500mg	zvzlrtfflg(talsvfivci) = nnvlzmsbwt vzobdekpua (rydwtrbfjs ) View more	Negative	18 Sep 2020
				Placebo + Fulvestrant 500mg	zvzlrtfflg(talsvfivci) = kqlmnyuvhy vzobdekpua (rydwtrbfjs ) View more